Mark Bhatt

Mark Bhatt employs chromatin accessibility profiling to understand how cancer cells reprogram their regulatory landscapes during oncogenesis and under therapeutic pressure. His ATAC-seq studies have defined enhancer rewiring events that activate oncogenes and suppress tumor suppressors in multiple cancer types. He has studied BET bromodomain inhibitor effects on super-enhancer-driven oncogene expression. His work demonstrates how chromatin accessibility changes can serve as biomarkers of therapeutic response and resistance.